finance.yahoo.com ·
Mannkind Corp Mnkd Reports Q1
Topic context
This topic has been covered 273322 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedMannKind's Q1 results show revenue growth from Furoscix and Tyvaso DPI, but operating costs surged due to scPharma acquisition. Upcoming FDA decisions (Afrezza pediatric, Furoscix ReadyFlow) and pipeline progress (Nintedanib DPI) are key catalysts. Commercial mechanism is weak: revenue growth is modest, cost increases pressure margins, and FDA outcomes are binary. No supply chain or scarcity signals.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Total revenues $90.2M in Q1 2026, +15% YoY
- Furoscix net sales $15.5M; Tyvaso DPI royalties +9%
- R&D expenses +56% to $17.2M; SG&A +116% to $54.1M (scPharma acquisition)
- PDUFA dates: Afrezza pediatric May 29; Furoscix ReadyFlow July 26
- Phase 1b Nintedanib DPI enrollment complete; Phase 2 expected Q2 2026
Afrezza, Furoscix, and Nintedanib DPI show flat to slightly up potential in the mid-term; window of 1-4 weeks.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHmid
Related stories
finance.yahoo.com
Ncmi Q1 2026 Earnings Transcript
finance.yahoo.com
Transcript Valneva Q1 2026 Earnings
zerohedge.com
Europe Primed Lower Open Amid Lack Progress Usiran Hefty Speaker Slate Nvidia Earnings Due
timesofindia.indiatimes.com
Fuel Rates Hiked Petrol Price Increased From Rs 94 77 to Rs 97 77 Diesel From Rs 87 67 to Rs 90 67 Check New List of Rates
auto.economictimes.indiatimes.com